The average one-year price target for Twist Bioscience (NasdaqGS:TWST) has been revised to 41.56 / share. This is an increase of 19.85% from the prior estimate of 34.68 dated January 16, 2024.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 25.25 to a high of 50.40 / share. The average price target represents an increase of 8.81% from the latest reported closing price of 38.20 / share.
What is the Fund Sentiment?
There are 465 funds or institutions reporting positions in Twist Bioscience. This is an increase of 27 owner(s) or 6.16% in the last quarter. Average portfolio weight of all funds dedicated to TWST is 0.19%, an increase of 32.97%. Total shares owned by institutions increased in the last three months by 0.58% to 81,523K shares. 
The put/call ratio of TWST is 1.37, indicating a bearish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 7,213K shares representing 12.48% ownership of the company. In it's prior filing, the firm reported owning 6,786K shares, representing an increase of 5.92%. The firm increased its portfolio allocation in TWST by 49.65% over the last quarter.
Jpmorgan Chase holds 4,616K shares representing 7.98% ownership of the company. In it's prior filing, the firm reported owning 5,068K shares, representing a decrease of 9.78%. The firm increased its portfolio allocation in TWST by 44.32% over the last quarter.
Artisan Partners Limited Partnership holds 3,723K shares representing 6.44% ownership of the company. In it's prior filing, the firm reported owning 1,762K shares, representing an increase of 52.68%. The firm increased its portfolio allocation in TWST by 248.89% over the last quarter.
ARKK - ARK Innovation ETF holds 3,638K shares representing 6.29% ownership of the company. In it's prior filing, the firm reported owning 3,733K shares, representing a decrease of 2.60%. The firm decreased its portfolio allocation in TWST by 2.77% over the last quarter.
Nikko Asset Management Americas holds 3,583K shares representing 6.20% ownership of the company. In it's prior filing, the firm reported owning 3,484K shares, representing an increase of 2.78%. The firm increased its portfolio allocation in TWST by 50.48% over the last quarter.
Twist Bioscience Background Information
(This description is provided by the company.)
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
